Dong-Hun Bae
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dong-Hun Bae has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Des Raymond Richardson
Centre for Cancer Cell Biology and Drug Discovery, Institute for Biomedicine and Glycomics, Griffith University, Southport, Queensland, Australia
15 shared publications - Patric Jan Jansson
Cancer Drug Resistance & Stem Cell Program, School of Medical Science, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia
11 shared publications - Darius J. R. Lane
Melbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, Kenneth Myer Building, The University of Melbourne, Parkville, Victoria 3052, Australia
10 shared publications - Sumit Sahni
Northern Clinical School, Faculty of Medicine and Health University of Sydney St Leonards New South Wales Australia
9 shared publications - Zaklina Kovacevic
Department of Physiology School of Biomedical Sciences Faculty of Medicine and Health University of NSW Sydney Australia
6 shared publications - Michael Li-Hsuan Huang
Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales, Australia
5 shared publications
Latest Publications
- 1 October 2020
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1866  (10) , 165844
Acireductone dioxygenase 1 (ADI1) is regulated by cellular iron by a mechanism involving the iron chaperone, PCBP1, with PCBP2 acting as a potential co-chaperone
- 1 October 2020
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1866  (10) , 165844
Acireductone dioxygenase 1 (ADI1) is regulated by cellular iron by a mechanism involving the iron chaperone, PCBP1, with PCBP2 acting as a potential co-chaperone
- 10 September 2020
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 33  (12) , 816-838
Ascorbate and Tumor Cell Iron Metabolism: The Evolving Story and Its Link to Pathology
Significance: Vitamin C or ascorbate (Asc) is a water-soluble vitamin and an antioxidant that is involved in many crucial biological functions. Asc's ability to reduce metals makes it an essential enzyme cofactor. Recent Advances: The ability of Asc to act as a reductant also plays an important part in its overall role in iron metabolism, where Asc induces both nontransferrin-bound iron and transferrin-bound iron uptake at physiological concentrations (∼50 μ M ). Moreover, Asc has emerged to play an important role in multiple diseases and its effects at pharmacological doses could be important for their treatment. Critical Issues: Asc's role as a regulator of cellular iron metabolism, along with its cytotoxic effects and different roles at pharmacological concentrations, makes it a candidate as an anticancer agent. Ever since the controversy regarding the studies from the Mayo Clinic was finally explained, there has been a renewed interest in using Asc as a therapeutic approach toward cancer due to its minimal side effects. Numerous studies have been able to demonstrate the anticancer activity of Asc through selective oxidative stress toward cancer cells via H 2 O 2 generation at pharmacological concentrations. Studies have demonstrated that Asc's cytotoxic mechanism at concentrations (>1 m M ) has been associated with decreased cellular iron uptake. Future Directions: Recent studies have also suggested other mechanisms, such as Asc's effects on autophagy, polyamine metabolism, and the cell cycle. Clearly, more has yet to be discovered about Asc's mechanism of action to facilitate safe and effective treatment options for cancer and other diseases.
- 10 September 2020
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 33  (12) , 816-838
Ascorbate and Tumor Cell Iron Metabolism: The Evolving Story and Its Link to Pathology
Significance: Vitamin C or ascorbate (Asc) is a water-soluble vitamin and an antioxidant that is involved in many crucial biological functions. Asc's ability to reduce metals makes it an essential enzyme cofactor. Recent Advances: The ability of Asc to act as a reductant also plays an important part in its overall role in iron metabolism, where Asc induces both nontransferrin-bound iron and transferrin-bound iron uptake at physiological concentrations (∼50 μ M ). Moreover, Asc has emerged to play an important role in multiple diseases and its effects at pharmacological doses could be important for their treatment. Critical Issues: Asc's role as a regulator of cellular iron metabolism, along with its cytotoxic effects and different roles at pharmacological concentrations, makes it a candidate as an anticancer agent. Ever since the controversy regarding the studies from the Mayo Clinic was finally explained, there has been a renewed interest in using Asc as a therapeutic approach toward cancer due to its minimal side effects. Numerous studies have been able to demonstrate the anticancer activity of Asc through selective oxidative stress toward cancer cells via H 2 O 2 generation at pharmacological concentrations. Studies have demonstrated that Asc's cytotoxic mechanism at concentrations (>1 m M ) has been associated with decreased cellular iron uptake. Future Directions: Recent studies have also suggested other mechanisms, such as Asc's effects on autophagy, polyamine metabolism, and the cell cycle. Clearly, more has yet to be discovered about Asc's mechanism of action to facilitate safe and effective treatment options for cancer and other diseases.
- 1 September 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1863  (9) , 1390-1397
The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance
- 1 September 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1863  (9) , 1390-1397
The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance
- Open Access
- 7 April 2019
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2019, 1-26
The Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases: Cross-Talk between Antioxidant Defense, Autophagy, and Apoptosis
The mitochondrion is an essential organelle important for the generation of ATP for cellular function. This is especially critical for cells with high energy demands, such as neurons for signal transmission and cardiomyocytes for the continuous mechanical work of the heart. However, deleterious reactive oxygen species are generated as a result of mitochondrial electron transport, requiring a rigorous activation of antioxidative defense in order to maintain homeostatic mitochondrial function. Indeed, recent studies have demonstrated that the dysregulation of antioxidant response leads to mitochondrial dysfunction in human degenerative diseases affecting the nervous system and the heart. In this review, we outline and discuss the mitochondrial and oxidative stress factors causing degenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and Friedreich’s ataxia. In particular, the pathological involvement of mitochondrial dysfunction in relation to oxidative stress, energy metabolism, mitochondrial dynamics, and cell death will be explored. Understanding the pathology and the development of these diseases has highlighted novel regulators in the homeostatic maintenance of mitochondria. Importantly, this offers potential therapeutic targets in the development of future treatments for these degenerative diseases.
- 7 April 2019
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2019, 1-26
Open AccessThe Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases: Cross-Talk between Antioxidant Defense, Autophagy, and Apoptosis
The mitochondrion is an essential organelle important for the generation of ATP for cellular function. This is especially critical for cells with high energy demands, such as neurons for signal transmission and cardiomyocytes for the continuous mechanical work of the heart. However, deleterious reactive oxygen species are generated as a result of mitochondrial electron transport, requiring a rigorous activation of antioxidative defense in order to maintain homeostatic mitochondrial function. Indeed, recent studies have demonstrated that the dysregulation of antioxidant response leads to mitochondrial dysfunction in human degenerative diseases affecting the nervous system and the heart. In this review, we outline and discuss the mitochondrial and oxidative stress factors causing degenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and Friedreich’s ataxia. In particular, the pathological involvement of mitochondrial dysfunction in relation to oxidative stress, energy metabolism, mitochondrial dynamics, and cell death will be explored. Understanding the pathology and the development of these diseases has highlighted novel regulators in the homeostatic maintenance of mitochondria. Importantly, this offers potential therapeutic targets in the development of future treatments for these degenerative diseases.
- Top Cited Papers
- 1 September 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1862  (9) , 2053-2068
The old and new biochemistry of polyamines
- 1 September 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1862  (9) , 2053-2068
Top Cited PapersThe old and new biochemistry of polyamines
- 1 September 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1864  (9) , 2793-2813
Coupling of the polyamine and iron metabolism pathways in the regulation of proliferation: Mechanistic links to alterations in key polyamine biosynthetic and catabolic enzymes
- 1 September 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1864  (9) , 2793-2813
Coupling of the polyamine and iron metabolism pathways in the regulation of proliferation: Mechanistic links to alterations in key polyamine biosynthetic and catabolic enzymes
- Open Access
- 1 March 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293  (10) , 3562-3587
Tumor stressors induce two mechanisms of intracellular P-glycoprotein–mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones
- 1 March 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293  (10) , 3562-3587
Open AccessTumor stressors induce two mechanisms of intracellular P-glycoprotein–mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones
- 1 March 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1862  (3) , 761-774
Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21 CIP1/WAF1 , by the chelator, Dp44mT
- 1 March 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1862  (3) , 761-774
Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21 CIP1/WAF1 , by the chelator, Dp44mT
- 1 May 2017
- Published by Elsevier in Pharmacological Research
- Vol. 119, 118-127
The mechanistic role of chemically diverse metal ions in the induction of autophagy
- 1 May 2017
- Published by Elsevier in Pharmacological Research
- Vol. 119, 118-127
The mechanistic role of chemically diverse metal ions in the induction of autophagy
- Open Access
- 1 January 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291  (3) , 1029-1052
The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways
- 1 January 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291  (3) , 1029-1052
Open AccessThe Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways